Global Adoption TheraPanacea’s ART-Plan radiotherapy platform is already deployed at over 60 cancer centres across Europe, Africa, the Middle East, and the US, indicating a ready-made expansion path for additional centers and new geographies.

Clinical Collaboration Strong partnerships with leading healthcare facilities and academic spin-off roots suggest a compelling value case for health system buyers seeking vendor credibility, clinical validation, and co-development opportunities.

Multi-Modality AI The ART-Omics platform enables AI-driven biomarker discovery integrated into clinical workflows, appealing to pharma sponsors and contract research organizations looking to accelerate trials and improve endpoint agility.

Expansion Footprint Recent facility expansion to Milan creates a strategic hub in Southern Europe, presenting a regional entry point for hospitals and research institutes in underserved markets and potential collaboration with European cancer centers.

Growth Readiness With mid-size company scale, a revenue range of $10–25M and a clear clinical impact story, TheraPanacea appears equipped to scale partnerships with mid-market biopharma, CROs, and health-tech distributors seeking validated AI in oncology.